Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
I am concerned that the recent article comparing various doses of bimatoprost
with both timolol maleate and a vehicle control1
may not fully represent all the data available to the authors. Laibovitz et
al appear to only report data that are favorable to bimatoprost while neglecting
other data that might produce a more balanced article.
The authors have conducted at least 2 similar studies,2
the first involving 60 patients (12 patients randomized to each of the treatment
groups) for 1 week and the second involving 100 patients (20 patients randomized
to each of the same treatment groups) who were followed for 1 month.1 In the study published in the July 2001 issue of
the ARCHIVES, the authors do not discuss both investigations and choose to
report just the second. The differences between these 2 short-term studies
are minor and include dosing, duration of the study (1 week vs 1 month), and
the frequency with which a technician personally administered the medications
(in the 1-week study, all drops were given by a technician, and in the present
study, a technician actually administered the medication only in the evening
before the next study visit).
Robin AL. An Accurate Comparison of Bimatoprost's Efficacy and Adverse Effects. Arch Ophthalmol. 2002;120(7):999-1000. doi: